Loading patent…
AssigneeEisai R&D Management Co., Ltd.
InventorsEiji INOUE, Akio YAMADA, Tomomi KAWAKATSU, Toshio IMAI, Maki DEGUCHI, Aki NAKATANI
Estimating the term…
Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.
-19. (canceled)
An isolated nucleic acid encoding an anti-EphA4 antibody, wherein the anti-EphA4 antibody comprises heavy and light chains, and comprises:
An isolated nucleic acid encoding an anti-EphA4 antibody, wherein the anti-EphA4 antibody comprises heavy and light chains, the heavy chain comprises a variable region consisting of the amino acid sequence shown in SEQ ID NO:45, and the light chain comprises a variable region consisting of the amino acid sequence shown in SEQ ID NO:46.
An isolated nucleic acid encoding an anti-EphA4 antibody, wherein the anti-EphA4 antibody comprises heavy and light chains, the heavy chain comprises the amino acid sequence shown in SEQ ID NO:59, and the light chain comprises the amino acid sequence shown in SEQ ID NO:60.
Dependencies are inferred from the claim text.